Literature DB >> 11089209

[Second primary carcinomas in the upper aerodigestive tract in different locations and age groups].

K Schwager1, A Nebel, G Baier, F Hoppe.   

Abstract

BACKGROUND: Second primary tumors are of great importance for diagnostics, therapy and prognosis in patients suffering from squamous cell carcinomas of the upper aerodigestive tract. The clinical observation of an increase of second primaries was the reason for analyzing all patients with head and neck cancer treated for a certain period of time at our institution.
METHODS: The hospital charts of 576 patients treated for squamous cell carcinoma of the oral cavity, the oropharynx, the hypopharynx and larynx treated from 1993 till 1996 at the Department of Otolaryngology, Head and Neck Surgery of the University of Würzburg were reviewed retrospectively.
RESULTS: 10.1% of all patients developed a second primary tumor. The rate was highest for patients with carcinoma of the oral cavity (17.5%), followed by tumors of the hypo- and oropharynx (11.7% and 11.5%) and the larynx (6.4%). Besides the location, younger age was detected as a risk factor for the formation of second malignancies. The latency between first and second primary tumor was 2.9 years in average. 31% of the second primaries were detected synchronous, 39% metachronous.
CONCLUSION: The results demonstrate that younger patients and patients with carcinomas of the upper digestive tract need a consequent follow-up. The development of second primaries even years after the first malignoma demonstrates the necessity of lifelong follow-up and oncological care.

Entities:  

Mesh:

Year:  2000        PMID: 11089209     DOI: 10.1055/s-2000-7675

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  2 in total

1.  [Patients with malignancies of the oro- and hypopharynx as well as the larynx. Significance/importance of oncological aftercare consultation].

Authors:  K Fritzsche; K Breitenstein; D Esser
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

2.  Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

Authors:  J Northover; R Glynne-Jones; D Sebag-Montefiore; R James; H Meadows; S Wan; M Jitlal; J Ledermann
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.